Gastrointestinal stromal tumour – adjuvant Initial PBS authority application Supporting information form (PB057)

This form is completed by the prescriber. You must lodge this form for a patient starting initial Pharmaceutical Benefits Scheme (PBS) subsidised treatment with imatinib mesylate following complete resection of primary gastrointestinal stromal tumour and who is at high risk of recurrence.


Page last updated: 5 February 2016

This information was printed Monday 26 September 2016 from It may not include all of the relevant information on this topic. Please consider any relevant site notices at when using this material.